دورية أكاديمية
Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.
| العنوان: | Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients. |
|---|---|
| المؤلفون: | Suyagh M; Clinical & Practice Research Group, School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, UK., Hawwa AF, Collier PS, Millership JS, Kole P, Millar M, Shields MD, Halliday HL, McElnay JC |
| المصدر: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2012 Nov; Vol. 74 (5), pp. 864-72. |
| نوع المنشور: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Validation Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: London, Macmillan Journals Ltd. |
| مواضيع طبية MeSH: | Models, Biological*, Canrenoic Acid/*pharmacokinetics , Canrenone/*pharmacokinetics , Chromatography, High Pressure Liquid/*methods, Administration, Intravenous ; Canrenoic Acid/administration & dosage ; Canrenoic Acid/therapeutic use ; Child ; Child, Preschool ; Critical Care ; Female ; Half-Life ; Humans ; Infant ; Infant, Newborn ; Male ; Mineralocorticoid Receptor Antagonists/administration & dosage ; Mineralocorticoid Receptor Antagonists/pharmacokinetics ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Nonlinear Dynamics ; Prospective Studies ; Tissue Distribution |
| مستخلص: | What Is Already Known About This Subject: Little is known about the pharmacokinetics of potassium canrenoate/canrenone in paediatric patients What This Study Adds: A population pharmacokinetic model has been developed to evaluate the pharmacokinetics of canrenone in paediatric patients who received potassium canrenoate as part of their therapy in the intensive care unit. AIMS To characterize the population pharmacokinetics of canrenone following administration of potassium canrenoate to paediatric patients. Methods: Data were collected prospectively from 23 paediatric patients (2 days to 10 years of age; median weight 4 kg, range 2.16-28.0 kg) who received intravenous potassium canrenoate (K-canrenoate) as part of their intensive care therapy for removal of retained fluids, e.g. in pulmonary oedema due to chronic lung disease and for the management of congestive heart failure. Plasma samples were analyzed by HPLC for determination of canrenone (the major metabolite and pharmacologically active moiety) and the data subjected to pharmacokinetic analysis using NONMEM. Results: A one compartment model best described the data. The only significant covariate was weight (WT). The final population models for canrenone clearance (CL/F) and volume of distribution (V/F) were CL/F (l h(-1) ) = 11.4 × (WT/70.0)(0.75) and V/F (l) = 374.2 × (WT/70) where WT is in kg. The values of CL/F and V/F in a 4 kg child would be 1.33 l h(-1) and 21.4 l, respectively, resulting in an elimination half-life of 11.2 h. Conclusions: The range of estimated CL/F in the study population was 0.67-7.38 l h(-1) . The data suggest that adjustment of K-canrenoate dosage according to body weight is appropriate in paediatric patients. (© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.) |
| References: | J Pharmacokinet Biopharm. 1992 Oct;20(5):511-28. (PMID: 1287200) Clin Pharmacol Ther. 1974 Aug;16(2):336-42. (PMID: 4368469) Eur J Clin Pharmacol. 1983;25(4):449-53. (PMID: 6653638) Biopharm Drug Dispos. 1993 Dec;14(9):721-66. (PMID: 8298069) Clin Pharmacokinet. 1996 May;30(5):329-32. (PMID: 8743333) J Lipid Res. 2005 Jun;46(6):1239-47. (PMID: 15772423) Pharmacogenetics. 2003 Jun;13(6):357-64. (PMID: 12777966) Pharm Res. 1995 Dec;12(12):1845-55. (PMID: 8786955) Paediatr Drugs. 2006;8(4):245-64. (PMID: 16898855) J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jul 24;839(1-2):36-44. (PMID: 16510319) Environ Health Perspect. 2003 Aug;111(11):1403-9. (PMID: 12928148) Br J Clin Pharmacol. 2004 Aug;58(2):142-55. (PMID: 15255796) J Pharmacol Exp Ther. 1973 Jun;185(3):686-95. (PMID: 4712657) AAPS J. 2005 Oct 05;7(2):E475-87. (PMID: 16353925) Annu Rev Pharmacol Toxicol. 2008;48:303-32. (PMID: 17914927) J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51. (PMID: 7334463) J Pharm Sci. 1971 May;60(5):708-15. (PMID: 5157180) |
| المشرفين على المادة: | 0 (Mineralocorticoid Receptor Antagonists) 78O20X9J0U (Canrenone) 87UG89VA9K (Canrenoic Acid) |
| تواريخ الأحداث: | Date Created: 20120302 Date Completed: 20130306 Latest Revision: 20211021 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC3495151 |
| DOI: | 10.1111/j.1365-2125.2012.04257.x |
| PMID: | 22376078 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2125 |
|---|---|
| DOI: | 10.1111/j.1365-2125.2012.04257.x |